210 Results for "

PI3Kα

" in MedChemExpress (MCE) Product Catalog:
Products (210)

210 Results for "PI3Kα" in MCE Product Catalog:

  • Isoforms Recommended:
1199
1199 Publications Verification
Cat. No.: HY-10108
CAS No.: 154447-36-6
Purity:  99.86%
Research Areas:  

Infection Cancer

LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively . LY294002 also inhibits CK2 with an IC50 of 98 nM . LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4 μM. LY294002 is an apoptosis activator [3].
loading...
    loading...
71
71 Cited Publications
Cat. No.: HY-15174
CAS No.: 1028385-32-1
Purity:  99.87%
Synonyms: BEZ235 Tosylate; NVP-BEZ 235 Tosylate
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.
loading...
    loading...
36
36 Cited Publications
Cat. No.: HY-15346
CAS No.: 1032568-63-0
Purity:  99.50%
Synonyms: BAY 80-6946
Target:  

PI3K Apoptosis

Research Areas:  

Cancer

Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .
loading...
    loading...
36
36 Cited Publications
Cat. No.: HY-15346A
CAS No.: 1402152-13-9
Purity:  99.55%
Synonyms: BAY 80-6946 dihydrochloride
Target:  

PI3K Apoptosis

Research Areas:  

Cancer

Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-13898
CAS No.: 1282512-48-4
Purity:  99.75%
Synonyms: GDC-0032; RG-7604
Target:  

PI3K

Research Areas:  

Cancer

Taselisib (GDC-0032) is a potent PI3K inhibitor targets PIK3CA mutations, with Kis of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-124719
CAS No.: 1402452-15-6
Purity:  99.82%
Target:  

PI3K mTOR GSK-3 CDK

Research Areas:  

Cancer

hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC50 of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) and CDK1/CDK2 (IC50=32/7.1 μM). hSMG-1 inhibitor 11j can be used for the research of cancer .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-15177
CAS No.: 1013101-36-4
Purity:  99.91%
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

PF-04691502 is a potent and selective inhibitor of PI3K and mTOR. PF-04691502 binds to human PI3Kα, β, δ, γ and mTOR with Kis of 1.8, 2.1, 1.6, 1.9 and 16 nM, respectively.
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-10683
CAS No.: 1173204-81-3
Purity:  99.17%
Target:  

PI3K mTOR

Research Areas:  

Cancer

PKI-402 is a selective, reversible, ATP-competitive inhibitor of PI3K, including PI3K-α mutants, and mTOR (IC50=2, 3, 7,14 and 16 nM for PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ).
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-12330
CAS No.: 1627494-13-6
Purity:  99.95%
Target:  

PI3K

Research Areas:  

Cancer

AZD8186 is a PI3K inhibitor, which potently inhibits PI3Kβ (IC50=4 nM) and PI3Kδ (IC5050=12 nM) with selectivity over PI3Kα (IC50=35 nM) and PI3Kγ (IC50=675 nM).
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-101562
CAS No.: 2060571-02-8
Purity:  99.96%
Synonyms: GDC-0077; RG6114
Target:  

PI3K Apoptosis

Research Areas:  

Cancer

Inavolisib (GDC-0077) is a potent, orally active, and selective PI3Kα inhibitor (IC50=0.038 nM). Inavolisib exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. Inavolisib is more selective for mutant versus wild-type PI3Kα. Inavolisib can be used for the study of breast cancer .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-12513
CAS No.: 1386874-06-1
Purity:  99.27%
Synonyms: LY3023414
Target:  

PI3K DNA-PK mTOR Autophagy

Research Areas:  

Cancer

Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits mTORC1/2 at low nanomolar concentrations .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-12034
CAS No.: 1062169-56-5
Purity:  98.04%
Target:  

mTOR Autophagy Apoptosis

Research Areas:  

Cancer

WYE-354 is an ATP-competitive mTOR inhibitor with an IC50 of 5 nM. WYE-354 also inhibits PI3Kα and PI3Kγ with IC50s of 1.89 μM and 7.37 μM, respectively. WYE-354 inhibits both mTORC1 and mTORC2. WYE-354 induces autophagy activation in vitro [3].
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10681
CAS No.: 1197160-78-3
Purity:  99.68%
Synonyms: PKI-587; PF-05212384
Target:  

PI3K mTOR

Research Areas:  

Cancer

Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively . Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2 .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-12046
CAS No.: 593960-11-3
Purity:  99.74%
Target:  

PI4K PI3K Virus Protease

Research Areas:  

Cancer

PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM, and also inhibits PI3Kγ and PI3Kα with IC50 of 16 nM and 39 nM, respectively.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-16526
CAS No.: 934526-89-3
Synonyms: XL-147; SAR245408
Target:  

PI3K

Research Areas:  

Cancer

Pilaralisib (XL147; SAR245408) is a potent and highly selective class I PI3Ks inhibitor with IC50s of 39 nM, 383 nM, 23 nM and 36 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-13334
CAS No.: 1245537-68-1
Purity:  99.92%
Synonyms: NVP-BGT226 maleate
Research Areas:  

Cancer

BGT226 (NVP-BGT226 maleate) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-13334A
CAS No.: 915020-55-2
Purity:  99.85%
Synonyms: NVP-BGT226
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-13440
CAS No.: 1253573-53-3
Purity:  99.38%
Target:  

PI3K

Research Areas:  

Cancer

AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks, with Kis of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively. AMG 511 significantly suppresses PI3K signaling that is indicated by p-Akt (Ser473) decrease. AMG 511 exhibits anti-tumor activity in mouse glioblastoma xenograft model .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-19962
CAS No.: 1382979-44-3
Synonyms: GDC-0084
Target:  

PI3K mTOR

Research Areas:  

Cancer

Paxalisib (GDC-0084) is a brain penetrant inhibitor of PI3K and mTOR, with Kis of 2 nM, 46 nM, 3 nM, 10 nM and 70 nM for PI3Kα PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-154848
CAS No.: 2919575-27-0
Purity:  99.98%
Target:  

PI3K Akt

UCL-TRO-1938 is a potent small molecule allosteric activator of PI3Kα with an EC50 value of approximately 60 μM. UCL-TRO-1938 can induce cell proliferation and has cardioprotective effects from ischaemia reperfusion injury and enhances nerve regeneration following nerve crush [3] .
loading...
    loading...